Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study

References

• Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397–403.
   PubMedGoogle Scholar
• Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008;19:1613–19.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: a crosstalk between the heart and kidney. Eur J Heart Fail 2010;12:1031–41.
   PubMed Web of Science ®Google Scholar
• London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 1997;4:194–211.
   PubMedGoogle Scholar
• Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125–34.
   PubMed Web of Science ®Google Scholar
• Taddei S, Nami R, Bruno RM, Quatrini I, Nuti R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev 2011;16:615–20.
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31–8.
   PubMed Web of Science ®Google Scholar
• Shastri S, Sarnak MJ. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010;56:399–417.
   PubMed Web of Science ®Google Scholar
• Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577–88.
   PubMed Web of Science ®Google Scholar
• Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007;103:416–19.
   PubMed Web of Science ®Google Scholar
• Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987;253:E675–83.
   PubMedGoogle Scholar
• Cotterill AM, Holly JM, Wass JA. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol (Oxf) 1993;39:357–62.
   PubMed Web of Science ®Google Scholar
• Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2009;24:778–87.
   PubMed Web of Science ®Google Scholar
• Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008;51:559–64.
   PubMed Web of Science ®Google Scholar
• Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007;104:16810–15.
   PubMed Web of Science ®Google Scholar
• Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73–81.
   PubMed Web of Science ®Google Scholar
• Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006;102:c21–9.
   PubMedGoogle Scholar
• Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998;18:404–10.
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the rennin–angiotensin system. J Clin Invest 2002;110:229–38.
   PubMed Web of Science ®Google Scholar
• Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac rennin–angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125–32.
   PubMed Web of Science ®Google Scholar
• Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007;103:521–4.
   PubMed Web of Science ®Google Scholar
• Resnick LM. Calciotropic hormones in salt-sensitive essential hypertension: 1,25-dihydroxyvitamin D and parathyroid hypertensive factor. J Hypertens Suppl 1994;12:S3–9.
   PubMedGoogle Scholar
• Christensen KL, Fenger-Gron M, Buus NH. Echocardiography of left ventricular mass in patients with essential hypertension. Ugeskr Laeger 2009;171:3252–5.
   PubMedGoogle Scholar
• Bruch C, Schmermund A, Dagres N, Katz M, Bartel T, Erbel R. Tei-index in coronary artery disease – validation in patients with overall cardiac and isolated diastolic dysfunction. Z Kardiol 2002;91:472–80.
   PubMedGoogle Scholar
• Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ, Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010;177:622–31.
   PubMed Web of Science ®Google Scholar
• Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988;108:524–9.
   PubMed Web of Science ®Google Scholar
• Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998;82:1071–6.
   PubMed Web of Science ®Google Scholar
• Lakoumentas JA, Panou FK, Kotseroglou VK, Aggeli KI, Harbis PK. The Tei index of myocardial performance: applications in cardiology. Hellenic J Cardiol 2005;46:52–8.
   PubMedGoogle Scholar
• Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:299–306.
   PubMed Web of Science ®Google Scholar
• Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754–9.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674–84.
   PubMed Web of Science ®Google Scholar
• Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest 2009;89:520–30.
   PubMed Web of Science ®Google Scholar
• Covic A, Voroneanu L, Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function – are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010;116:c187–95.
   PubMedGoogle Scholar
• Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009;20:2651–60.
   PubMed Web of Science ®Google Scholar
• Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther 2008;22:37–44.
   PubMed Web of Science ®Google Scholar